Trizzino John

SEC source: 0000904454-20-000592 · edgar.xml · derivative · entry 17

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,249 shares

Expires 2026-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the March 15, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 16

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,087

F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.81 to $154.25, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 15

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,387

F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.78 to $153.69, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 14

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,095

F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.76 to $152.74, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 13

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,294

F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.59 to $151.35, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 12

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,304

F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.59 to $150.50, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 11

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,104

F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.52 to $149.50, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 10

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,704

F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.52 to $148.51, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 9

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,805

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.52 to $147.51, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 8

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,899

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.52 to $146.51, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 7

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,799

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.99 to $144.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 6

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,099

F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.31 to $143.19, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 5

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,875

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 4

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,465

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 3

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,143

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 2

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,191

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000904454-20-000592 · edgar.xml · nonDerivative · entry 1

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,336

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-20-078321 · tm2023761-2_4.xml · derivative · entry 1

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

Underlying: Common Stock · 2,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan will vest on each of the first three (3) anniversaries of the June 25, 2020 grant date, subject to continued employment through each such vesting date.

F2 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan will vest on each of the first three (3) anniversaries of the June 25, 2020 grant date, subject to continued employment through each such vesting date.

SEC source: 0001104659-20-078296 · tm2023760-4_4.xml · derivative · entry 1

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-09-26

F1 · date: This option award was previously reported based on having been approved by the issuer's board of directors on September 26, 2019, but such award was subject to shareholder approval of an increase in the number of shares available for issuance under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). Such shareholder approval was received on June 25, 2020.

F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan will vest on the first anniversary of the September 26, 2019 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.

SEC source: 0001209191-20-017736 · doc4.xml · derivative · entry 3

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 468 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on satisfaction of both (1) a time-based vesting requirement, pursuant to which one hundred percent (100%) of the RSUs vested on the first anniversary of the March 8, 2019 grant date subject to continued employment through such vesting date; and (2) a performance-based vesting requirement, pursuant to which one hundred percent (100%) of the RSUs vested based on the Company's achievement of a regulatory milestone associated with NanoFlu on or before September 30, 2019.

F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on satisfaction of both (1) a time-based vesting requirement, pursuant to which one hundred percent (100%) of the RSUs vested on the first anniversary of the March 8, 2019 grant date subject to continued employment through such vesting date; and (2) a performance-based vesting requirement, pursuant to which one hundred percent (100%) of the RSUs vested based on the Company's achievement of a regulatory milestone associated with NanoFlu on or before September 30, 2019.

SEC source: 0001209191-20-017736 · doc4.xml · nonDerivative · entry 2

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,087

SEC source: 0001209191-20-017736 · doc4.xml · nonDerivative · entry 1

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,268

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

SEC source: 0000904454-19-000658 · edgar.xml · derivative · entry 4

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-09-26

F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan will vest on the first anniversary of the Grant Date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date and subject to shareholder approval of an increase in the number of shares available for issuance under the Plan.

SEC source: 0000904454-19-000658 · edgar.xml · derivative · entry 3

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,400

Underlying: Common Stock · 18,400 shares

Expires 2029-09-26

F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan will vest on the first anniversary of the Grant Date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date and subject to shareholder approval of an increase in the number of shares available for issuance under the Plan.

SEC source: 0000904454-19-000658 · edgar.xml · derivative · entry 2

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,613

Underlying: Common Stock · 10,613 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through such vesting date.

F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through such vesting date.

SEC source: 0000904454-19-000658 · edgar.xml · derivative · entry 1

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,900

Underlying: Common Stock · 31,900 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest one (1) year from the September 26, 2019 grant date (the "Grant Date"), subject to continued employment with the Company through the vesting date.

F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest one (1) year from the September 26, 2019 grant date (the "Grant Date"), subject to continued employment with the Company through the vesting date.

SEC source: 0001104659-20-078296 · tm2023760-4_4.xml · derivative · entry 2

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,400

Underlying: Common Stock · 18,400 shares

Expires 2029-09-26

F3 · security: Represents the previously reported September 26, 2019 stock appreciation right grant. The Form 4 filed by the reporting person on September 30, 2019 inadvertently stated that vesting of this grant was subject to shareholder approval of an increase in the number of shares available for issuance under the Plan. However, this grant was not subject to such shareholder approval.

F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this stock appreciation right grant under the Plan will vest on the first anniversary of the Grant Date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.

SEC source: 0001209191-19-049314 · doc4.xml · nonDerivative · entry 1

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,800

F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.69 to $5.75, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0001209191-19-049019 · doc4.xml · derivative · entry 3

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,143 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested six (6) months from the March 8, 2019 grant date subject to continued employment with the Company through the vesting date.

F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested six (6) months from the March 8, 2019 grant date subject to continued employment with the Company through the vesting date.

SEC source: 0001209191-19-049019 · doc4.xml · nonDerivative · entry 2

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,378

SEC source: 0001209191-19-049019 · doc4.xml · nonDerivative · entry 1

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,091

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

SEC source: 0001209191-19-018990 · doc4.xml · derivative · entry 2

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,887

Underlying: Common Stock · 46,887 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F3 · derivative.exercise_date: Vesting of the RSUs subject to this grant under the Plan is subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which one hundred percent (100%) of the RSUs vesting on the first anniversary of the Grant Date subject to continued employment through such vesting date; and (2) performance-based vesting requirements, pursuant to which (i) 80% of the RSUs will vest based on achieving a regulatory milestone associated with ResVax on or before September 30, 2019; or (ii) 20% of the RSUs will vest based on achieving a regulatory milestone associated with NanoFlu on or before September 30, 2019.

F3 · derivative.expiration_date: Vesting of the RSUs subject to this grant under the Plan is subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which one hundred percent (100%) of the RSUs vesting on the first anniversary of the Grant Date subject to continued employment through such vesting date; and (2) performance-based vesting requirements, pursuant to which (i) 80% of the RSUs will vest based on achieving a regulatory milestone associated with ResVax on or before September 30, 2019; or (ii) 20% of the RSUs will vest based on achieving a regulatory milestone associated with NanoFlu on or before September 30, 2019.

SEC source: 0001209191-19-018990 · doc4.xml · derivative · entry 1

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,861

Underlying: Common Stock · 102,861 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F2 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest six (6) months from the March 8, 2019 grant date (the "Grant Date") subject to continued employment with the Company through the vesting date.

F2 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest six (6) months from the March 8, 2019 grant date (the "Grant Date") subject to continued employment with the Company through the vesting date.

SEC source: 0001209191-18-062768 · doc4.xml · derivative · entry 1

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2028-12-13

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.

SEC source: 0001209191-18-030108 · doc4.xml · nonDerivative · entry 1

Trizzino John · CIK 0001468534 · SVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,965

SEC source: 0001209191-17-066329 · doc4.xml · derivative · entry 1

Trizzino John · CIK 0001468534 · SVP, Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2027-12-15

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.

SEC source: 0001209191-17-007074 · doc4.xml · nonDerivative · entry 1

Trizzino John · CIK 0001468534 · SVP, Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,965

F1 · balance_after: Includes 3,401 shares acquired under the Issuer's Amended and Restated 2013 Employee Stock Purchase Plan on January 31, 2017.

SEC source: 0001209191-16-150734 · doc4.xml · derivative · entry 2

Trizzino John · CIK 0001468534 · SVP, Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2026-11-14

F2 · derivative.exercise_date: Vesting of the shares subject to this option grant under the Plan is subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vesting on the first anniversary of the Grant Date, and the remaining seventy-five percent (75%) of the shares vesting in equal monthly installments over the following three (3) years subject to continued employment through such vesting date; and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares will vest if, at any time during the four-year period from the Grant Date, the volume-weighted average stock price of Novavax' common stock meets or exceeds $4.00, $6.00, or $8.00, respectively, for twenty (20) consecutive trading days.

SEC source: 0001209191-16-150734 · doc4.xml · derivative · entry 1

Trizzino John · CIK 0001468534 · SVP, Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2026-11-14

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. 2015 Stock Incentive Plan, as amended (the "Plan") vest on the first anniversary of the November 14, 2016 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.

SEC source: 0001209191-16-142676 · doc4.xml · nonDerivative · entry 1

Trizzino John · CIK 0001468534 · SVP, Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,564